GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amphastar Pharmaceuticals Inc (NAS:AMPH) » Definitions » PE Ratio

Amphastar Pharmaceuticals (Amphastar Pharmaceuticals) PE Ratio

: 15.51 (As of Today)
View and export this data going back to 2014. Start your Free Trial

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-04-19), Amphastar Pharmaceuticals's share price is $40.01. Amphastar Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $2.58. Therefore, Amphastar Pharmaceuticals's PE Ratio for today is 15.51.


The historical rank and industry rank for Amphastar Pharmaceuticals's PE Ratio or its related term are showing as below:

AMPH' s PE Ratio Range Over the Past 10 Years
Min: 9.15   Med: 41.31   Max: 9685
Current: 15.51


During the past 13 years, the highest PE Ratio of Amphastar Pharmaceuticals was 9685.00. The lowest was 9.15. And the median was 41.31.


AMPH's PE Ratio is ranked better than
69.89% of 611 companies
in the Drug Manufacturers industry
Industry Median: 22.79 vs AMPH: 15.51

Amphastar Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $0.68. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $2.58.

As of today (2024-04-19), Amphastar Pharmaceuticals's share price is $40.01. Amphastar Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $3.18. Therefore, Amphastar Pharmaceuticals's PE Ratio without NRI for today is 12.58.

During the past 13 years, Amphastar Pharmaceuticals's highest PE Ratio without NRI was 496.67. The lowest was 9.05. And the median was 38.54.

Amphastar Pharmaceuticals's EPS without NRI for the three months ended in Dec. 2023 was $0.88. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $3.18.

During the past 12 months, Amphastar Pharmaceuticals's average EPS without NRI Growth Rate was 49.40% per year. During the past 3 years, the average EPS without NRI Growth Rate was 342.50% per year.

During the past 13 years, Amphastar Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 342.50% per year. The lowest was -48.00% per year. And the median was 3.60% per year.

Amphastar Pharmaceuticals's EPS (Basic) for the three months ended in Dec. 2023 was $0.75. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $2.84.


Amphastar Pharmaceuticals PE Ratio Historical Data

The historical data trend for Amphastar Pharmaceuticals's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amphastar Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PE Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.68 670.33 18.63 16.10 23.79

Amphastar Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PE Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.10 20.95 29.47 17.96 23.79

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amphastar Pharmaceuticals PE Ratio Distribution

For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where Amphastar Pharmaceuticals's PE Ratio falls into.



Amphastar Pharmaceuticals PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Amphastar Pharmaceuticals's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=40.01/2.580
=15.51

Amphastar Pharmaceuticals's Share Price of today is $40.01.
Amphastar Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.58.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio or PE Ratio (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Amphastar Pharmaceuticals  (NAS:AMPH) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Amphastar Pharmaceuticals PE Ratio Related Terms

Thank you for viewing the detailed overview of Amphastar Pharmaceuticals's PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Amphastar Pharmaceuticals (Amphastar Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
11570 6th Street, Rancho Cucamonga, CA, USA, 91730
Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
Executives
Mary Z. Luo director, 10 percent owner, officer: COO and Chief Scientist 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Floyd F. Petersen director 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Rong Zhou officer: EVP, Production C/O AMPHASTAR PHARMACEUTICALS INC., 11570 SIXTH STREET, RANCHO CUCAMONGA CA 91730
Richard K Prins director
William J Peters officer: CFO, SVP & Treasurer C/O AMPHASTAR PHARMACEUTICALS, INC., 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Yakob Liawatidewi officer: SVP Corp Admin Center C/O AMPHASTAR PHARMACEUTICALS INC, 11570 SIXTH STREET, RANCHO CUCAMONGA CA 91730
Michael A Zasloff director
Gayle Deflin director 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Diane G. Gerst officer: EVP, QA & Regulatory Affairs 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Howard Lee director 13F-2, NO. 36, LANE 48, SECTION 3, NAN-JING EAST ROAD, TAIPEI, TAIWAN F4 00000
Jack Y. Zhang director, 10 percent owner, officer: CEO & Chief Scientific Officer 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
David Maris director C/O AMPHASTAR PHARMACEUTICALS, INC., 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Richard Koo director 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Jason B. Shandell director, officer: President 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Applied Physics & Chemistry Laboratories, Inc. 10 percent owner 13760 MAGNOLIA AVENUE, CHINO CA 91710